36 related articles for article (PubMed ID: 38455982)
1. Vogt-Koyanagi-Harada Disease: A Narrative Review.
Tayal A; Daigavane S; Gupta N
Cureus; 2024 Apr; 16(4):e58867. PubMed ID: 38800227
[TBL] [Abstract][Full Text] [Related]
2. [Vogt-Koyanagi-Harada disease].
Bonnet C; Daudin JB; Monnet D; Brézin A
J Fr Ophtalmol; 2017 Jun; 40(6):512-519. PubMed ID: 28579215
[TBL] [Abstract][Full Text] [Related]
3. Uveitis and serous retinal detachment secondary to systemic dabrafenib and trametinib.
Rueda-Rueda T; Sánchez-Vicente JL; Moruno-Rodríguez A; Molina-Socola FE; Martínez-Borrego AC; López-Herrero F
Arch Soc Esp Oftalmol (Engl Ed); 2018 Sep; 93(9):458-462. PubMed ID: 29580759
[TBL] [Abstract][Full Text] [Related]
4. VKH-like syndrome in the setting of Dabrafenib and Trametinib therapy for BRAF mutant metastatic melanoma: a case report.
Gunaratnam C; Muzicenco O; Sivagurunathan P; Franzco MH
J Surg Case Rep; 2024 Mar; 2024(3):rjae104. PubMed ID: 38455982
[TBL] [Abstract][Full Text] [Related]
5. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
Madoe A; Schauwvlieghe PP; Jacob J
Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
[TBL] [Abstract][Full Text] [Related]
6. Vogt-Kayanagi-Harada-Like Uveitis Induced by Dabrafenib/Trametinib Therapy for Cutaneous Malignant Melanoma.
Kaymak NZ; Kaplan AT
Ophthalmic Surg Lasers Imaging Retina; 2023 Aug; 54(8):477-480. PubMed ID: 37535619
[TBL] [Abstract][Full Text] [Related]
7. Choroidal thickening with serous retinal detachment in BRAF/MEK inhibitor-induced uveitis: A case report.
Kiraly P; Groznik AL; Valentinčič NV; Mekjavić PJ; Urbančič M; Ocvirk J; Mesti T
World J Clin Cases; 2022 Jul; 10(19):6536-6542. PubMed ID: 35979276
[TBL] [Abstract][Full Text] [Related]
8. Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report.
Lim J; Lomax AJ; McNeil C; Harrisberg B
Ocul Immunol Inflamm; 2018; 26(4):628-631. PubMed ID: 27892777
[TBL] [Abstract][Full Text] [Related]
9. Ocular side effects of Trametinib and Dabrafenib: a case report.
Tarım B; Kılıç M
J Ophthalmic Inflamm Infect; 2023 Apr; 13(1):17. PubMed ID: 37046057
[TBL] [Abstract][Full Text] [Related]
10. Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database.
Mettler C; Monnet D; Kramkimel N; Tréluyer JM; Mouthon L; Brézin A; Dupin N; Valnet-Rabier MB; Chouchana L; Terrier B
Ophthalmology; 2021 Dec; 128(12):1748-1755. PubMed ID: 34000304
[TBL] [Abstract][Full Text] [Related]
11. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
12. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
[TBL] [Abstract][Full Text] [Related]
13. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma.
Brambati M; Giuffrè C; Marchese A; Bandello F; Modorati GM; Miserocchi E
Eur J Ophthalmol; 2022 Jan; 32(1):NP109-NP113. PubMed ID: 32998540
[TBL] [Abstract][Full Text] [Related]
14. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]